La Jolla Pharmaceutical aims to eliminate tissue damage. The company is working to develop tissue-repair compounds based on a cell-stimulating regenerative medicine technology. It is focused on skin and lung tissue, cardiac muscle, cartilage, and bone repair. La Jolla Pharmaceutical had previously ceased most of its operations after trials of lupus candidate Riquent failed in 2009. After exploring its options, the firm began searching for new potential pharmaceutical candidates to develop. In 2011 La Jolla found a new focus when it acquired a regenerative medicine program for tissue repair from private research firm GliaMed.